An article reports that Bristol Myers Squibb’s Opdivo (nivolumab) and Merck’s Keytruda (pembrolizumab), both well-known checkpoint inhibitors utilized in treating multiple cancer types, will be the subjects of a U.S. FDA advisory panel meeting scheduled for September 26. The intent of the meeting is not specified in the brief excerpt provided. Sarah Silbiger is credited with the accompanying image.

Source link